Nicolas Lanthier
YOU?
Author Swipe
View article: Management of Wilson disease across Europe: an international physician-oriented survey by the ERN-RARE Liver group
Management of Wilson disease across Europe: an international physician-oriented survey by the ERN-RARE Liver group Open
Background Wilson disease (WD) is a rare disorder resulting in copper overload. Diagnosis and treatment are complex and highly specialized. We aimed to investigate the management of WD across Europe in line with the mission and framework o…
View article: Therapeutic plasma exchange in amatoxin associated acute liver failure–results from the multi-center Amanita-PEX study
Therapeutic plasma exchange in amatoxin associated acute liver failure–results from the multi-center Amanita-PEX study Open
View article: Early diagnosis of liver graft steatosis and fibrosis: are non-invasive tests the answer?
Early diagnosis of liver graft steatosis and fibrosis: are non-invasive tests the answer? Open
TE may be useful for screening advanced fibrosis and, interestingly, steatosis after LT. TE might gain relevance to track graft metabolic dysfunction and to propose lifestyle interventions.
View article: Non‐Cirrhotic Steatotic Liver Disease is Associated With Impaired Muscle Function: A Cross‐Sectional Study
Non‐Cirrhotic Steatotic Liver Disease is Associated With Impaired Muscle Function: A Cross‐Sectional Study Open
Background Impaired muscle function is frequent in cirrhosis and potentially participates in liver disease progression. Data from non‐cirrhotic patients with steatotic liver disease (SLD) are lacking. Our aims were to determine if muscle f…
View article: Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver
Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver Open
View article: Myosteatosis in Oesophagogastric Cancer: A Systematic Review
Myosteatosis in Oesophagogastric Cancer: A Systematic Review Open
View article: Co-existing regeneration mechanisms in severe alcohol-related steatohepatitis
Co-existing regeneration mechanisms in severe alcohol-related steatohepatitis Open
In biopsy-proven cases of sASH, proliferation of hepatocytes and K7+ cells occurs in parallel. This could suggest that liver progenitor cells begin to replicate even in the absence of massive hepatocyte senescence in humans, or …
View article: Evaluation of a Ten-Antigen Immunodot Test in Autoimmune Hepatitis and Primary Biliary Cholangitis: Lessons Learned for a Tertiary Care Academic Hospital
Evaluation of a Ten-Antigen Immunodot Test in Autoimmune Hepatitis and Primary Biliary Cholangitis: Lessons Learned for a Tertiary Care Academic Hospital Open
Autoimmune diseases of the liver and biliary tract require timely and accurate diagnosis. This study evaluates the D-tek panel (D-Tek, Mons, Belgium) of 10 immunodot antigens for its effectiveness in diagnosing autoimmune hepatitis (AIH) a…
View article: Evaluation of a Ten Immunodot Antigens Test in Autoimmune Hepatitis and Primary Biliary Cholangitis, Lessons Learned for a Tertiary Care Academic Hospital
Evaluation of a Ten Immunodot Antigens Test in Autoimmune Hepatitis and Primary Biliary Cholangitis, Lessons Learned for a Tertiary Care Academic Hospital Open
Autoimmune diseases of the liver and biliary tract require timely and accurate diagnosis. This study evaluates the D-tek panel (D-Tek, Mons, Belgium) of 10 immunodot antigens for its effectiveness in diagnosing autoimmune hepatitis (AIH) a…
View article: What references and what gold standard should be used to assess myosteatosis in chronic liver disease?
What references and what gold standard should be used to assess myosteatosis in chronic liver disease? Open
View article: Metabolic dysfunction-associated steatotic liver disease : the tree that hides the forest?
Metabolic dysfunction-associated steatotic liver disease : the tree that hides the forest? Open
The world of hepatology has been recently shaken by a much-needed change of nomenclature validated by a large expert consensus (1). This consensus finally adopts positive diagnostic criteria for the recently renamed metabolic dysfunction-a…
View article: In Memoriam: René Fiasse (1936-2024)
In Memoriam: René Fiasse (1936-2024) Open
It is with great sadness that we learned of the death of Professor René Fiasse on the 26th of February 2024, at the age of 87. Born in Quiévrain in 1936 in the Borinage region, to two teachers, he was the eldest of four children. From an e…
View article: Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?
Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease? Open
Myosteatosis is highly prevalent in metabolic dysfunction‐associated steatotic liver disease (MASLD) and could reciprocally impact liver function. Decreasing muscle fat could be indirectly hepatoprotective in MASLD. We conducted a review t…
View article: Intestinal FGF15 regulates bile acid and cholesterol metabolism but not glucose and energy balance
Intestinal FGF15 regulates bile acid and cholesterol metabolism but not glucose and energy balance Open
Fibroblast growth factor 15/19 (FGF15/19, mouse/human ortholog) is expressed in the ileal enterocytes of the small intestine and released postprandially in response to bile acid absorption. Previous reports of FGF15-/- mice have limited ou…
View article: Jaundice with severe leucocytosis
Jaundice with severe leucocytosis Open
View article: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Open
Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov nu…
View article: Pirfenidone-induced liver injury, a case report of a rare idiosyncratic reaction
Pirfenidone-induced liver injury, a case report of a rare idiosyncratic reaction Open
Nearly all medications carry the risk of drug-induced liver injury (DILI). Idiosyncratic reactions are rare and poorly predictable, and the mechanisms are not always well understood. Pirfenidone is an oral antifibrotic drug used to treat i…
View article: Impact of Peroxisome Proliferator-Activated Receptor Agonists on Myosteatosis in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease
Impact of Peroxisome Proliferator-Activated Receptor Agonists on Myosteatosis in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease Open
The combination of different PPAR agonists could have a positive impact on reducing myosteatosis, in addition to their effect on the liver. Some discrepancies could be explained by the different techniques used to assess muscle lipid conte…
View article: Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease
Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease Open
View article: Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review
Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review Open
View article: Cell transplantation-based regenerative medicine in liver diseases
Cell transplantation-based regenerative medicine in liver diseases Open
View article: A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Patients
A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Patients Open
Simple bioclinical tools allowed routine triage of T2DM patients for MAFLD severity, with high adherence of high-risk patients to subsequent noninvasive exams.
View article: Clinical nutrition, skeletal muscle and liver disease: linking the dots for good management
Clinical nutrition, skeletal muscle and liver disease: linking the dots for good management Open
This is not new. The famous phrase “Let your food be your medicine and your medicine be your food” is attributed to Hippocrates of Kos in ancient Greece (1). In the mid-twentieth century, based on their clinical experience, two surgeons, C…
View article: Are elevated systemic bile acids involved in the pathophysiology of sarcopenia and liver injury following gastric bypass?
Are elevated systemic bile acids involved in the pathophysiology of sarcopenia and liver injury following gastric bypass? Open
Bariatric surgery is currently the most effective treatment for sustained weight loss in severe obesity. However, recent data describe the development of liver damage and in particular massive steatosis and cholangitis in some patients, fo…
View article: Impairment of aryl hydrocarbon receptor signalling promotes hepatic disorders in cancer cachexia
Impairment of aryl hydrocarbon receptor signalling promotes hepatic disorders in cancer cachexia Open
Background The aryl hydrocarbon receptor (AHR) is expressed in the intestine and liver, where it has pleiotropic functions and target genes. This study aims to explore the potential implication of AHR in cancer cachexia, an inflammatory an…
View article: Metabolic steatosis: recent scientific data also support a change in nomenclature
Metabolic steatosis: recent scientific data also support a change in nomenclature Open
Two years ago, many experts spoke out in favour of changing the nomenclature of the most common liver disease in the world, non-alcoholic fatty liver disease (NAFLD) (1). This was the subject of an editorial in the Acta Gastroenterologica …
View article: Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues
Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues Open
View article: Pathophysiological changes of the liver-muscle axis in end-stage liver disease: what is the right target?
Pathophysiological changes of the liver-muscle axis in end-stage liver disease: what is the right target? Open
Liver diseases and in particular end stage liver diseases are frequently complicated by muscle modifications that are linked to worse clinical outcome. In addition, recent studies have demonstrated the negative impact of these muscle chang…
View article: Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations
Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations Open
Background Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease in the world. Progression toward non-alcoholic steatohepatitis (NASH) is associated with alterations of skeletal muscle. One p…
View article: Liver Fetuin-A at Initiation of Insulin Resistance
Liver Fetuin-A at Initiation of Insulin Resistance Open
Hepatokines (liver secreted proteins with possible distant action) are emerging potential players in insulin resistance in type 2 diabetic patients. Here, we explored the effect of a high-fat diet on the expression of fetuin-A, one of thos…